Are there generic versions of Bosulif on the market?
No, no generic versions of Bosulif (bosutinib) are currently available. The brand-name drug, made by Pfizer, holds the market exclusively due to active patents and regulatory protections.[1]
When do Bosulif patents expire?
Key U.S. patents for Bosulif extend protection through at least 2031, with the primary compound patent (U.S. Patent 7,342,013) expiring October 2, 2031. Pediatric exclusivity adds six months, pushing full expiry to April 2, 2032. Multiple secondary patents cover formulations and methods of use, some lasting until 2036.2
What FDA approvals block generics?
Bosulif has orphan drug exclusivity until December 8, 2026, for chronic myeloid leukemia treatment, preventing generic approval even if patents allow. No ANDAs (Abbreviated New Drug Applications) for bosutinib have received FDA tentative or final approval.1
Who is challenging Bosulif patents?
Pfizer faces Paragraph IV challenges from generic makers like MSN Laboratories and Dr. Reddy's Laboratories, who filed ANDAs claiming non-infringement. Litigation is ongoing in federal court, with no settlements disclosed that would speed generic entry.2
When might generics launch?
Earliest realistic U.S. generic entry aligns with patent expiry in 2031-2032, barring successful litigation or settlements. In Europe, some bosutinib patents expired earlier, but no generics are marketed there yet due to supplementary protections.2
How does Bosulif compare to generic alternatives?
No direct generics exist, but physicians sometimes switch to other TKIs like generic imatinib (Gleevec generics since 2016) or dasatinib (Sprycel generics since 2025) for CML, based on mutation profiles and resistance. Bosutinib remains preferred for later-line therapy.[1]
Sources
[1]: FDA Orange Book